Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
tbsnews48m
US FDA approves Pfizer's drug for rare bleeding disorder
The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older ...
FiercePharma1d
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
The Pharma Letter9h
FDA approves new treatment for hemophilia A or B
The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...
Managed Healthcare Executive1d
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents
Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...
hemophilianewstoday1d
FDA approves marstacimab, now Hympavzi, for hemophilia
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
devdiscourse1d
Current Health News: From Transplants to Bird Flu
The summary covers major health news, including six transplant patients in Brazil contracting HIV from infected organs, ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...
Daily1d
FDA Approves New new treatment option for cutting bleeding in Hemophilia A or B
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
Medscape1d
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.